IFM DUE

IFM Due, a subsidiary of IFM Therapeutics, is a biopharmaceutical company developing small-molecule, orally available drug candidates targeting aberrant inflammatory responses of the innate immune system triggered by the cGAS-STING pathway, which is believed to underlie a variety of serious diseases.